AU2006268034B2 - Diagnostic method for brain damage-related disorders - Google Patents

Diagnostic method for brain damage-related disorders Download PDF

Info

Publication number
AU2006268034B2
AU2006268034B2 AU2006268034A AU2006268034A AU2006268034B2 AU 2006268034 B2 AU2006268034 B2 AU 2006268034B2 AU 2006268034 A AU2006268034 A AU 2006268034A AU 2006268034 A AU2006268034 A AU 2006268034A AU 2006268034 B2 AU2006268034 B2 AU 2006268034B2
Authority
AU
Australia
Prior art keywords
protein
gstp
stroke
polypeptide
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006268034A
Other languages
English (en)
Other versions
AU2006268034A1 (en
Inventor
Denis Francois Hochstrasser
Jean-Charles Sanchez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Geneve
Original Assignee
Universite de Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Geneve filed Critical Universite de Geneve
Publication of AU2006268034A1 publication Critical patent/AU2006268034A1/en
Application granted granted Critical
Publication of AU2006268034B2 publication Critical patent/AU2006268034B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
AU2006268034A 2005-07-14 2006-07-14 Diagnostic method for brain damage-related disorders Active AU2006268034B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0514435A GB2428240A (en) 2005-07-14 2005-07-14 Diagnostic method for brain damage-related disorders
GB0514435.7 2005-07-14
PCT/GB2006/050207 WO2007007129A2 (en) 2005-07-14 2006-07-14 Diagnostic method for brain damage-related disorders

Publications (2)

Publication Number Publication Date
AU2006268034A1 AU2006268034A1 (en) 2007-01-18
AU2006268034B2 true AU2006268034B2 (en) 2012-02-02

Family

ID=34897198

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006268034A Active AU2006268034B2 (en) 2005-07-14 2006-07-14 Diagnostic method for brain damage-related disorders

Country Status (10)

Country Link
US (1) US9028825B2 (https=)
EP (1) EP1902319B1 (https=)
JP (2) JP5281397B2 (https=)
AT (1) ATE456055T1 (https=)
AU (1) AU2006268034B2 (https=)
CA (1) CA2613991C (https=)
DE (1) DE602006011896D1 (https=)
ES (1) ES2336946T3 (https=)
GB (1) GB2428240A (https=)
WO (1) WO2007007129A2 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9929140D0 (en) * 1999-12-10 2000-02-02 Univ Geneve Diagnostic assay for stroke
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
DK2021792T3 (da) * 2006-05-09 2013-05-21 Univ British Columbia Opløste protein-artritmarkører
DE102006048201A1 (de) * 2006-10-11 2008-04-17 Ganymed Pharmaceuticals Ag Autoantigene zur verbesserten Diagnose, Prognose und Therapie von entzündlichen neurologischen Erkrankungen
WO2009036336A2 (en) * 2007-09-12 2009-03-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomarkers for motor neuron disease
US9079947B2 (en) 2007-11-27 2015-07-14 The University Of British Columbia 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
DK2240781T3 (en) 2008-01-18 2018-03-26 Harvard College METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS
US20120003225A1 (en) * 2008-05-09 2012-01-05 Duke University Autoantibodies in the detection and treatment of cancer
ES2665245T3 (es) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
JP5755149B2 (ja) * 2009-01-26 2015-07-29 エレクトロフォレティクス リミテッドＥｌｅｃｔｒｏｐｈｏｒｅｔｉｃｓ Ｌｉｍｉｔｅｄ 方法
US8486652B2 (en) * 2009-01-30 2013-07-16 Bio-Rad Innovations Method for the in vitro diagnosis of stroke
CA2754741C (en) 2009-03-11 2019-02-12 Augurex Life Sciences Corporation Compositions and methods for characterizing arthritic conditions
EP2462444B1 (en) * 2009-08-07 2018-10-03 Affinimark Technologies, Inc. Methods for the immunological identification of cerebrospinal fluid
WO2011032155A2 (en) 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
RU2422095C1 (ru) * 2009-12-11 2011-06-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования эффективности местной химиотерапии при лечении больных злокачественными опухолями головного мозга
WO2011106322A2 (en) * 2010-02-23 2011-09-01 The Govt. Of The U.S.A. As Represented By The Secretary, Department Of Health And Human Services. Biomarkers for acute ischemic stroke
GB201008541D0 (en) * 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
EP2596134B1 (en) 2010-07-23 2020-04-08 President and Fellows of Harvard College Methods of detecting diseases or conditions using phagocytic cells
WO2012012693A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
EP2628013B1 (en) 2010-10-14 2019-06-12 The Johns Hopkins University Biomarkers of brain injury
WO2012081701A1 (ja) 2010-12-16 2012-06-21 独立行政法人産業技術総合研究所 髄液型糖タンパク質の富化及び分離方法、並びにその方法を用いた中枢神経系疾患用マーカーの探索方法及び中枢神経系疾患用マーカー
WO2012152970A1 (es) * 2011-05-06 2012-11-15 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol Método de diagnóstico del ictus isquémico
JP2014518624A (ja) 2011-05-12 2014-08-07 ザ・ジョンズ・ホプキンス・ユニバーシティー ニューログラニン診断キットのためのアッセイ試薬
EP2758781A4 (en) 2011-09-22 2015-05-27 Bio Rad Laboratories SYSTEMS AND METHOD FOR BIOCHEMICAL DATA ANALYSIS
AU2012325604B2 (en) 2011-10-21 2017-08-03 Augurex Life Sciences Corp. Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013090285A1 (en) * 2011-12-14 2013-06-20 University Of Rochester Method of diagnosing mild traumatic brain injury
US9709573B2 (en) 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
EP2841945A4 (en) * 2012-04-24 2016-04-27 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING OF STROKE OR OTHER BRAINS
EP2861788B1 (en) 2012-06-15 2018-10-10 Progenity, Inc. Methods of detecting diseases or conditions using circulating diseased cells
WO2013188846A1 (en) 2012-06-15 2013-12-19 Harry Stylli Methods of detecting diseases or conditions
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
CN111426848A (zh) * 2013-06-28 2020-07-17 株式会社 Mcbi 认知功能障碍疾病的生物标记物及使用该生物标记物的认知功能障碍疾病的检测方法
EP3022322A4 (en) 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
MA40636A (fr) 2014-09-11 2015-09-11 Colleen Kelly Procédés pour détecter le cancer de la prostate
FI20155280L (fi) * 2015-04-15 2016-10-16 Medicortex Finland Oy Aivovamman prognostisia ja diagnostisia glykaanipohjaisia biomarkkereita
CN105506083B (zh) * 2015-12-24 2018-10-19 孙梅芬 Capg在制备诊断帕金森症产品中的用途
JP6947451B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
WO2018002362A1 (en) * 2016-06-30 2018-01-04 Randox Laboratories Ltd Measurement of fabp for diagnosis
EP3506927A4 (en) 2016-08-03 2020-05-06 University of South Florida REELIN COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASES
WO2018030252A1 (ja) * 2016-08-09 2018-02-15 大塚製薬株式会社 尿バイオマーカーを用いたアルツハイマー病の診断補助方法
US10914748B2 (en) 2016-09-08 2021-02-09 UNIVERSITé LAVAL Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing Parkinson's disease
KR102806918B1 (ko) * 2016-09-16 2025-05-14 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
KR102466369B1 (ko) * 2020-08-04 2022-11-14 서울대학교병원 자가면역 뇌염의 진단 방법
JP7569552B2 (ja) * 2021-01-29 2024-10-18 国立大学法人東北大学 認知症診断用のバイオマーカー
CN114966045A (zh) * 2022-05-07 2022-08-30 浙江大学 检测抗肌球蛋白轻链1-IgG自身抗体的试剂在制备检测血管内皮损伤的试剂盒中的应用
CN115166260B (zh) * 2022-07-11 2023-06-13 东南大学 血浆脑细胞来源外泌体中维生素d结合蛋白在诊断抑郁症中的应用
CN118624905B (zh) * 2023-07-31 2025-04-01 中国人民解放军总医院第一医学中心 一种糖尿病性肾病诊断的生物标志物和试剂盒及诊断设备
CN120820725B (zh) * 2025-09-17 2026-01-27 上海交通大学医学院附属仁济医院 胶质纤维酸性蛋白和乳酸脱氢酶a亚型在制备诊断颅脑创伤的试剂盒中的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017A (en) * 1845-05-01 Reid r
US3015A (en) * 1843-03-21 Improvement in gilding, silvering
GB225245A (en) * 1923-11-23 1924-12-24 British Thomson Houston Co Ltd Improvements in and relating to elastic fluid turbines
GB322063A (en) * 1928-10-29 1929-11-28 Godwin Stanley Oliver Improvements relating to automatic vehicle-controlled track-signalling devices
JPH09110713A (ja) * 1995-10-13 1997-04-28 Nippon Green Ueebu Kk グルタチオン−ｓ−トランスフェラーゼ活性化剤並びにそれを含む医薬品及び飲食物
EP0914452A2 (en) * 1996-06-17 1999-05-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel ptp20, pcp-2, bdp1, clk and sirp proteins and related products and methods
US6541615B1 (en) * 1996-11-15 2003-04-01 Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. SIRP proteins and uses thereof
CA2263063C (en) * 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
AU1701001A (en) * 1999-11-30 2001-06-12 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibodies against signal regulator proteins
GB9929140D0 (en) 1999-12-10 2000-02-02 Univ Geneve Diagnostic assay for stroke
ATE368858T1 (de) 2000-03-10 2007-08-15 Univ Geneve Verfahren zur diagnose von transmissiblen spongiformen encephalopathien
GB2360089A (en) * 2000-03-10 2001-09-12 Univ Geneve Diagnostic assay for transmisible spongiform encephalopathies
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
AU2003274368B2 (en) * 2002-10-30 2008-11-20 Proteome Sciences Plc. Diagnostic method for transmissible spongiform encephalopathies (prion diseases)
DK2357477T3 (en) * 2003-09-20 2018-02-05 Electrophoretics Ltd Diagnostic approach for brain injury-related disorders based on detection of NDKA
JP2007518062A (ja) * 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
GB0419124D0 (en) 2004-08-27 2004-09-29 Proteome Sciences Plc Methods and compositions relating to Alzheimer's disease
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
EP1825274B1 (en) 2004-12-07 2009-11-18 Electrophoretics Limited Monitoring Huntington's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pierre Lescuyer et al, " Identification of postmortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration" Proteomics. 2004 Aug;4(8):2234-41 *

Also Published As

Publication number Publication date
GB2428240A (en) 2007-01-24
ES2336946T3 (es) 2010-04-19
EP1902319B1 (en) 2010-01-20
GB0514435D0 (en) 2005-08-17
US9028825B2 (en) 2015-05-12
US20080220013A1 (en) 2008-09-11
DE602006011896D1 (de) 2010-03-11
WO2007007129A3 (en) 2007-05-31
CA2613991C (en) 2017-03-07
WO2007007129A2 (en) 2007-01-18
JP5281397B2 (ja) 2013-09-04
EP1902319A2 (en) 2008-03-26
ATE456055T1 (de) 2010-02-15
AU2006268034A1 (en) 2007-01-18
CA2613991A1 (en) 2007-01-18
JP2013092538A (ja) 2013-05-16
JP2009501333A (ja) 2009-01-15

Similar Documents

Publication Publication Date Title
AU2006268034B2 (en) Diagnostic method for brain damage-related disorders
Hergenroeder et al. Identification of serum biomarkers in brain-injured adults: potential for predicting elevated intracranial pressure
Öhrfelt et al. Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method
EP3271728A1 (en) Materials and methods for diagnosis and treatment of alzheimer's disease
DK2389587T3 (en) Diagnostic and prognostic methods related Alzheimer's Disease
US20170254818A1 (en) Cns-specific biomarkers for cns diseases or injuries
CA2800038A1 (en) Diagnostic methods
US20090275046A1 (en) Complement factor H protein as a biomarker of Parkinson's disease
Thouvenot et al. Enhanced detection of CNS cell secretome in plasma protein-depleted cerebrospinal fluid
KR102547505B1 (ko) 주요 우울 장애 치료 효과 조기 예측용 바이오마커
WO2007140971A2 (en) Cell adhesion proteins as biomarker for alzheimer's disease
US20130236917A1 (en) Albumin-bound protein/peptide complex as a biomarker for disease
US20170030929A1 (en) Diagnosis of chronic kidney disease by quantitative analysis of post-translational modifications of plasma proteins
WO2007140976A2 (en) Enzymes as biomarker for alzheimer's disease
JP2009052933A (ja) プリオン病の検出方法及び診断キット
JP2026501271A (ja) シヌクレインペプチドの検出方法
Ferrara The unbiased search of biomarkers in neurodegenerative diseases
Frankenfeld Proteomic analysis of human cerebrospinal fluid of patients with major depressive disorder and schizophrenia
Chen TMI on TBI: Multi-Approach Proteomics Discovery of Traumatic Brain Injury Biomarkers
Carrette et al. Proteomic Applications for Molecular Assessment of Alzheimer's Disease
Lim et al. disease patients [version 1; peer review: awaiting peer review]
Lim et al. Putative autoantibodies in the cerebrospinal fluid of Alzheimer’s
CA2961520A1 (en) Markers for mood disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)